This is a prospective pilot study designed to demonstrate the impact of circadian rhythm on the spread of Circulating Tumor Cells (CTCs) in patients with Non- Small Cell Lung Cancer - NSCLC. 27 patients will be included in the study and will be followed for 12 months. For each included patient, blood samples will be collected before the anticancer treatment initiation.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
27
* at 4:00 a.m. * at 10:00 a.m. Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable).
Hôpital Larrey
Toulouse, France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, France
Presence of CTCs detected with the CellSearch technique.
Time frame: 12 months after the end of inclusions
Quantification of CTCs by the CellSearch technique and expressed in number of cells / millilitre of blood.
Time frame: 12 months after the end of inclusions
Quantification of CTCs by the ParSortix technique and expressed in number of cells / millilitre of blood.
Time frame: 12 months after the end of inclusions
Objective response defined as complete or partial response.
Response will be assessed according to the clinician's judgment.
Time frame: 12 months after the end of inclusions
Progression-free survival (PFS) defined as the time between the date of inclusion and the date of first progression or death.
Time frame: 12 months after the end of inclusions
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.